DIA Makes Key Appointment in China
DIA China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
DIA (Drug Information Association) China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
Dong previously held executive positions as CEO for Lilly China Research and Development Co., a subsidiary of Eli Lilly and Company, and was president and CEO of IMPACT Therapeutics, Inc. He has been employed by Roche in China and the U.S., and by other Chinese and international companies, working in R&D, sales and marketing, business development and executive management.
Dong is a full professor at Nanjing University of Technology, and was named a “Leading Talent in Creativity, Innovation and Entrepreneurship” by the Nanjing New & High Technology Industry Development Zone. He holds an MBA from the China Europe International Business School and a doctorate in chemistry from the University of Washington.
This appointment was prompted by the retirement of Jane Cai, PhD, from the role of DIA China regional director. Under her direction, DIA China was established in 2011 as a legal entity, DIA Beijing Healthcare Information Consulting Ltd. Also, participation of attendees and exhibitors in DIA China Annual Meeting participation doubled, as did membership numbers.
Read the full release here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
